A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with
ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.